Maegim한국어

한독

002390KOSPISector: Pharma & Biotech
₩8,230 0.96%Market cap ₩113.3BAs of Jul 21, 2026 close · updated once daily
C
Grade C50.4 ptsTop 53% of 2,523 stocks
Financial strength
34.1
Growth momentum
48.4
Price attractiveness
70.4

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

34.1
How much debt does it carry relative to equity?
Debt-to-equity ratio
184.1%
Below median · Top 89.6% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
77.0%
Below median · Top 83.5% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
0.6%
Above median · Top 45.5% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-0.8%
Above median · Top 44.9% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original

2

Growth momentum

48.4
How much did revenue grow in a year?
Revenue growth (YoY)
5.5%
Below median · Top 55% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
-0.5%
Below median · Top 69.5% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
511.2%
Above median · Top 3.8% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-88.4%
Below median · Top 78.2% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original

3

Price attractiveness

70.4
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 52.6% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.41x
Above median · Top 6.7% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15